hackint0sh/New-Dataset huggingface dataset:
For the main PLIMeC study we will use a mixed method approach, combining various data collection and analysis methods (qualitative and quantitative). Quantitative methods will be used to obtain a breadth of understanding of the phenomenon of interest, and qualitative methods will be used to explore and obtain depth of this understanding. More specifically, the combination of methods will be used for complementarity, using qualitative data to examine how the participants, patients and healthcare providers, experience this specific CL-psychiatric intervention and quantitative methods to examine the impact of such an intervention on patients. In data analysis, the priority among the two methods will be equal. primaryPurpose: HEALTH_SERVICES_RESEARCH masking: NONE count: 30 type: ESTIMATED name: Intervention arm - Consultation-Liaison (CL) brief psychiatric intervention in primary care settings name: Control Arm - Treatment As Usual (TAU) measure: Evaluate the feasibility of the main PLIMeC study measure: Mental health - psychiatric symptoms measure: Mental health - Quality of life measure: Mental health - Self-report questionnaire measure: The lived experience of the participants measure: The lived experience of the implicated clinicians measure: Healthcare system complexity - Quantitative assessment measure: Healthcare system complexity - qualitative assessment measure: Access to mental healthcare sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Center for Primary Care and Public Health (Unisanté) - Sponsorship / Not recruiting site city: Lausanne state: Vaud zip: 1010 country: Switzerland lat: 46.516 lon: 6.63282 facility: Service de psychiatrie de l'adulte nord ouest (SPANO) Département de psychiatrie - CHUV (DP-CHUV) city: Yverdon-les-Bains state: Vaud zip: 1400 country: Switzerland name: Julien Elowe, MD role: CONTACT phone: 0041 21 314 54 38 email: Julien.Elowe@chuv.ch name: Julien Elowe, MD role: PRINCIPAL_INVESTIGATOR name: Gerrit Weber, MD role: SUB_INVESTIGATOR lat: 46.77852 lon: 6.64115 facility: Centre Neuchâtelois de Psychiatrie (CNP) city: Neuchâtel zip: 2000 country: Switzerland name: Stéphane Saillant, PD role: CONTACT phone: 0041 32 755 15 15 email: stephane.saillant@cnp.ch name: Stéphane Saillant, PD role: PRINCIPAL_INVESTIGATOR name: Julie Gavin-Ramain, PhD role: SUB_INVESTIGATOR lat: 46.99179 lon: 6.931 hasResults: False
nctId: NCT06377176 id: NTUNHSEN briefTitle: Postpartum Massage Therapy for Women and Infants: The Effect on Maternal Depression, Stress, Fatigue and Infant Temperament overallStatus: COMPLETED date: 2021-06-16 date: 2021-10-03 date: 2021-10-03 date: 2024-04-22 date: 2024-04-22 name: National Taipei University of Nursing and Health Sciences class: OTHER briefSummary: Mother and infant massage, a type of complementary therapy, possesses the capacity to ameliorate maternal depression, stress, fatigue, and also infant temperaments and convert them into more manageable ones. The objective of this study was to determine the effect of mother and infant massage therapy on maternal depression, stress, fatigue, and infant temperament. In this quasi-experimental study, a total of 102 participants were allocated into two groups based on a pretest and posttest. During a period of five weeks, the experimental groups were subjected to ten massages per week, twice every week. On the data, a generalized estimating equation (GEE) was implemented. This study's hypothesis was an improvement in maternal depression, stress, fatigue, and infant temperament. conditions: Postpartum Depression studyType: INTERVENTIONAL phases: NA allocation: NON_RANDOMIZED interventionModel: PARALLEL interventionModelDescription: A quasi-experimental design was utilized in this investigation; it comprised a pre-test and a post-test administered to two distinct groups. The intervention group was subjected to pre-testing before receiving the intervention, and after the intervention, mother and infant massage treatment was delivered to the intervention group. Post-testing was performed on both groups, with the control group receiving mother and infant massage. primaryPurpose: TREATMENT masking: NONE count: 102 type: ACTUAL name: Massage therapy measure: Depression measure: Stress measure: Fatigue measure: Infant temperament sex: ALL minimumAge: 1 Month maximumAge: 50 Years stdAges: CHILD stdAges: ADULT facility: Community Health Center city: Sleman state: Yogyakarta zip: 55584 country: Indonesia lat: -7.71556 lon: 110.35556 hasResults: False
nctId: NCT06377163 id: acquired pneumonia in children briefTitle: Bacterial Pathogens Associated With Community-acquired Pneumonia in Children overallStatus: COMPLETED date: 2021-01-01 date: 2021-08-31 date: 2021-08-31 date: 2024-04-22 date: 2024-04-22 name: Delta University for Science and Technology class: OTHER briefSummary: Pediatric community acquired pneumonia (CAP) is one of the most common reasons for hospital admission, there is no reliable way of distinguishing the causative organism based on clinical features.
This study examined common pathogens of community-acquired pneumonia from 28 days up to 10 years in Dakahlia Governorate. conditions: Children Pneumonia studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: RETROSPECTIVE count: 100 type: ACTUAL measure: Complete blood count measure: C-reactive protein (CRP) measure: Blood culture and sensitivity on admission measure: Gastric lavage culture or sputum culture on admission sex: ALL minimumAge: 28 Days maximumAge: 10 Years stdAges: CHILD facility: Amira Hussin Mohammed city: Gamasa zip: 35712 country: Egypt lat: 31.44112 lon: 31.53675 hasResults: False
nctId: NCT06377150 id: ABCA4-1382022BO2 briefTitle: Stargardt Disease in Childhood overallStatus: COMPLETED date: 2022-04-01 date: 2024-03-31 date: 2024-03-31 date: 2024-04-22 date: 2024-04-22 name: University Hospital Tuebingen class: OTHER briefSummary: Retrospective chart review study to elucidate the phenotype and genotype of children with ABCA4-associated Stargardt disease. conditions: Stargardt Disease studyType: OBSERVATIONAL observationalModel: COHORT timePerspective: CROSS_SECTIONAL count: 39 type: ACTUAL measure: Best Corrected Visual Acuity (BCVA) measure: Visual Field (VF) measure: Fundus Photography (FP) measure: Fundus Autofluorescence (AF) measure: Optical Coherence Tomography (OCT) measure: Full-Field Electroretinography (ff-ERG) sex: ALL stdAges: CHILD stdAges: ADULT stdAges: OLDER_ADULT facility: University Hospital Tuebingen city: Tuebingen state: Baden-Wuerttemberg, Germany zip: 72076 country: Germany lat: 48.52266 lon: 9.05222 hasResults: False
nctId: NCT06377137 id: University of the Porto briefTitle: High-intensity Small-sided Soccer Games for Cardiometabolic Health in Adolescents With Metabolic Dysfunction overallStatus: COMPLETED date: 2023-03-10 date: 2023-04-10 date: 2023-09-01 date: 2024-04-22 date: 2024-04-22 name: Universidade do Porto class: OTHER briefSummary: Pediatric obesity is considered one of the most important public health problems worldwide due to its high prevalence and associated comorbidities. Physical exercise has been shown to have an important role in the treatment of obesity and associated cardiometabolic dysfunction. Small-sided soccer games (SSSG) have been explored as a promising way of increasing physical exercise due to its benefits on cardiometabolic health and high degree of enjoyment, which favors long-term adherence.
A parallel 3-arm randomized controlled trial will be conducted in adolescents with overweight and metabolic dysfunction between 11 and 15 years of age. The inclusion criteria are: (i) age between 11-15 years at the time of intervention start; (ii) overweight or obesity (BMI\> 85th percentile); (iii) Abdominal obesity ≥90th percentile as assessed by waist circumference or a waist-to-height ratio ≥ 0.5; (iv) willing to participate in the study regardless of possible group allocation; (v) informed consent given by participant and legal representatives. Exclusion criteria: (i) health condition not compatible with participation in physical exercise; (ii) history of recent musculoskeletal injury hindering exercise participation; (iii) concurrent participation in a structured weight loss or exercise program.
Those eligible to participate in the study will be randomly assigned to one of three groups: i) SSSG group, ii) traditional soccer play group (TSG), or, iii) non-exercise intervention control group (CG). Participants in both exercise intervention groups will undergo a 16-week intervention. The SSSG group will participate in a high-intensity small-sided soccer games training, while the TSG will undergo a technical and tactical skills training program and traditional soccer training. The CG participants will continue with regular school physical education classes without any additional intervention. Before and after the intervention, all participants will be assessed for cardiometabolic and hepatic biochemical markers, physical fitness, anthropometry and body composition, blood pressure, objective daily physical activity and sleep quality, and perceived enjoyment of participation in SSSG and TSG. The primary outcomes of the study will be waist circumference and cardiorespiratory fitness.
The study protocol was approved by the Ethics Committee of the Faculty of Sport of the University of Porto and by the Scientific Ethics Committee of the Adventist University of Chile. conditions: Obesity, Adolescent conditions: Metabolic Syndrome studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: SINGLE whoMasked: OUTCOMES_ASSESSOR count: 51 type: ACTUAL name: Small-sided soccer games groups (SSSG) name: Traditional soccer training groups (TSG) measure: Waist circumference measure: Cardiorespiratory fitness measure: Variation in fasting blood glucose concentration (mg/dL) measure: Variation in serum insulin concentration (mU/L) measure: Variation in HOMA-IR measure: Variation in glycosylated hemoglobin concentration (mg/dL) measure: Variation in high-density lipoprotein cholesterol concentration (mg/dL) measure: Variation in low-density lipoprotein cholesterol concentration (mg/dL) measure: Variation in total cholesterol concentration (mg/dL) measure: Variation in blood triglycerides concentration (mg/dL) measure: Variation in blood Alanine aminotransferase concentration (U/L) measure: Variation in blood Aspartate aminotransferase concentration (U/L) measure: Variation in blood Gamma glutamyl transferase concentration (U/L) measure: 6-minute walk test measure: Hand grip strength measure: Lower limb strength measure: Body composition measure: Body mass index measure: Neck circumference measure: Blood Pressure (mmHg) measure: Physical activity measure: Sleep quality measure: Perceived enjoyment of physical activity sex: MALE minimumAge: 11 Years maximumAge: 15 Years stdAges: CHILD facility: Faculty of Sport of the University of Porto city: Porto zip: 4200-450 country: Portugal lat: 41.14961 lon: -8.61099 hasResults: False
nctId: NCT06377124 id: UW21-507 briefTitle: A Smart Self-Management Support Programme (3S) to Improve Quality of Life in Lung Cancer Patients overallStatus: NOT_YET_RECRUITING date: 2024-04-22 date: 2026-03-31 date: 2026-06-30 date: 2024-04-22 date: 2024-04-22 name: The University of Hong Kong class: OTHER name: Queen Mary Hospital, Hong Kong name: The Queen Elizabeth Hospital name: United Christian Hospital briefSummary: Lung cancers patients often experience multiple symptoms (e.g. fatigue, dyspnea, distress, depression, sleep disturbance). The current study attempts to explore the efficacy of the Smart Self-Management Support Programme (3S) in improving quality of life of patients using self-management support programme with mobile devices. conditions: Lung Cancer studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: The 3S intervention includes an individual session, messaging and phone contact related to lung cancer self-management, and hotline services.
The general health information includes an individual session, messaging and phone contact related to general health information, and hotline services. primaryPurpose: SUPPORTIVE_CARE masking: SINGLE maskingDescription: The outcome assessor was not aware of which groups the patients belonged to. whoMasked: OUTCOMES_ASSESSOR count: 320 type: ESTIMATED name: 3S intervention name: GH information measure: Change in health-related quality of life measure: Change in health-related quality of life measure: Change in patient activation measure: Change in general self-efficacy measure: Change in acceptance of illness measure: Change in physical activity level measure: Change in diet habit measure: Change in smoking and drinking habits measure: Change in health status measure: Change in anxiety symptoms of patients measure: Change in depression symptoms of patients measure: Change in social and family support measure: Change in adherence to agreed preset health-related goals measure: Change in symptom severity measure: Change in functional exercise capacity measure: Change in lower limb strength measure: Change in hand grip strength measure: Change in flexibility measure: Change in balance measure: Change in body composition measure: Change in objective physical activity level measure: Change in objective sleep quality measure: Change in burden of family caregivers (For FCGs) measure: Change in quality of life of family caregivers (For FCGs) measure: Change in anxiety symptoms of family caregivers (For FCGs) measure: Change in depression symptoms of family caregivers (For FCGs) sex: ALL minimumAge: 18 Years maximumAge: 100 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Queen Mary Hospital city: Hong Kong country: Hong Kong name: Agnes YK Lai, PhD role: CONTACT phone: 3970-2903 email: ayklai@hkmu.edu.hk name: Agnes Yuen Kwan Lai, PhD role: PRINCIPAL_INVESTIGATOR lat: 22.27832 lon: 114.17469 hasResults: False
nctId: NCT06377111 id: PANTHEON-IO briefTitle: A Study to Test the Benefit of Vitamin B5 in Patients With Melanoma overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-05 date: 2024-04-22 date: 2024-04-22 name: University Health Network, Toronto class: OTHER briefSummary: This study is open to patients with a type of cancer called melanoma. Patients can join the study if their tumor cannot be removed by surgery or has spread to other organs, and are planned to receive immunotherapy as treatment for their cancer. This study is looking at whether taking calcium pantothenate supplement (a type of Vitamin B5) can increase its levels in the blood and have an effect in the immune system, when its used in combination with the immunotherapy. conditions: Melanoma (Skin) studyType: INTERVENTIONAL phases: PHASE1 allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: TREATMENT masking: NONE count: 12 type: ESTIMATED name: C-PAN name: Nivolumab name: Ipilimumab measure: To determine if the dose of 2000 mg daily of pantothenic acid achieves an increase in plasmatic concentration of pantothenic acid by at least a 50% between baseline and week 9, in 9 or more of the patients treated with combined ICI. measure: Evaluate the overall response rate (ORR) of the enrolled cohort. measure: Evaluate the progression free survival (PFS) of the enrolled cohort. measure: Incidence of immune-related colitis. measure: Correlation between baseline intestinal microbiome composition to the development of immune-related colitis. measure: Correlation between the early changes in composition of intestinal microbiome and the development of immune-related colitis. measure: The incidence of treatment-related adverse events. measure: The incidence of treatment-related adverse events measure: Correlation between change in plasmatic pantothenic acid level between baseline and at first day of ICI, and ORR. measure: Correlation between change in pantothenic acid plasmatic level in mcMol/L between baseline and first day of ICI, and ORR by RECIST and iRECIST. measure: Correlation between change in plasmatic pantothenic acid level between baseline and week 9 assessment, and immune profiling. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University Health Network- Princess Margaret Cancer Centre city: Toronto state: Ontario zip: M5G 2M9 country: Canada name: Minge Xu role: CONTACT phone: 416-946-4501 phoneExt: 7754 email: minge.xu@uhn.ca name: Samuel Saibil role: PRINCIPAL_INVESTIGATOR lat: 43.70011 lon: -79.4163 hasResults: False
nctId: NCT06377098 id: UAB-300010901 id: UAB Dixon Endowed Ch/3102800 type: OTHER_GRANT domain: UAB Dixon Endowed Chair briefTitle: Intrapartum Sildenafil in Laboring Mothers acronym: PRISM overallStatus: NOT_YET_RECRUITING date: 2024-06-01 date: 2024-12-31 date: 2028-01-31 date: 2024-04-22 date: 2024-04-22 name: University of Alabama at Birmingham class: OTHER name: University Teaching Hospital, Lusaka, Zambia name: Egerton University name: Cameroon Baptist Convention Health briefSummary: The goal of this feasibility pilot clinical trial is to learn if sildenafil citrate 50mg orally, up to three times during labor, can be appropriately administered, with limited clinical side effects, to laboring mothers to determine feasibility across a spectrum of available healthcare resources.
The results of this feasibility pilot trial will be used to inform the design and conduct of a large pragmatic randomized controlled trial to determine if sildenafil citrate, compared to placebo, will decrease fetal distress and perinatal asphyxia. conditions: Neonatal Asphyxia conditions: Intrapartum Fetal Distress conditions: Development, Infant conditions: Intrapartum Asphyxia studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Double blinded, placebo-controlled, 1:1 parallel allocation, randomized feasibility trial primaryPurpose: TREATMENT masking: QUADRUPLE maskingDescription: The only person who will be unmasked will be the pharmacist who will dispense the study medication--either sildenafil 50mg or identical placebo whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1000 type: ESTIMATED name: Sildenafil 50 mg Oral Tablet name: Placebo Oral Tablet measure: Percentage of perinatal mortality measure: Percentage of operative delivery measure: Indication for operative delivery measure: Percentage of mothers who received fetal heart rate monitoring measure: Indication for fetal heart rate monitoring measure: Apgar Score measure: Percentage of use of bag and mask ventilation in neonates measure: Percentage of neonates with neonatal encephalopathy measure: Percentage of neonates with neonatal encephalopathy measure: Percentage of neonates with hypoxemia measure: Percentage of infants with neonatal hypoxic-ischemic encephalopathy measure: Percentage of neonatal ICU admissions measure: Percentage of maternal rehospitalization measure: Percentage of neonatal rehospitalization measure: Infant/child developmental assessment sex: ALL minimumAge: 0 Days maximumAge: 40 Years stdAges: CHILD stdAges: ADULT facility: Cameroon Baptist Convention Health Services city: Douala country: Cameroon name: Pius Tih Muffih, PhD role: CONTACT phone: 677764781 email: piustih@cbchealthservices.org name: Rahel Kyeng Mbah role: CONTACT phone: 370 371378 email: kyeng2003@yahoo.co.uk name: Akila Subramaniam, MD role: PRINCIPAL_INVESTIGATOR name: Pius Tih Miffih, PhD role: SUB_INVESTIGATOR lat: 4.04827 lon: 9.70428 facility: Egerton University/Nakuru County Referral Hospital city: Nakuru country: Kenya name: Amos Otara, MD role: CONTACT phone: 254 7222 7470 email: amosotara@yahoo.com name: Elizabeth G Kibaru, MbchB, Mmed role: CONTACT phone: 072 942 394 email: ekibaru@egerton.ac.ke name: Nora Switchenko, MD role: PRINCIPAL_INVESTIGATOR name: Amos Otara, MD role: SUB_INVESTIGATOR lat: -0.28333 lon: 36.06667 facility: University Teaching Hospital city: Lusaka country: Zambia name: Elwyn Chomba, MD role: CONTACT phone: 0211 254 655 email: elwynchomba@gmail.com name: Musaku Mwenechanya, MD role: CONTACT phone: +260966722966 email: mmusaku@gmail.com name: Elwyn Chomba, MD role: PRINCIPAL_INVESTIGATOR name: Musaku Mwenechanya, MD role: SUB_INVESTIGATOR lat: -15.40669 lon: 28.28713 hasResults: False
nctId: NCT06377085 id: 809325 briefTitle: Repurposing 5-Azacytidine for the Treatment of Muscle Contractures in Children With Cerebral Palsy overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-05 date: 2026-05 date: 2024-04-22 date: 2024-04-22 name: Shirley Ryan AbilityLab class: OTHER name: Rady Children's Hospital, San Diego briefSummary: In this controlled dose-escalation study, we will study the initial safety, biological properties, and potential efficacy of 5-azacytidine (AZA). Our overarching aspiration is for AZA to evolve into an approved pharmacological treatment, fostering muscle growth and enhancing body movement, ultimately contributing to an improved quality of life in children with CP.
Researchers will compare participants with four different dosages of AZA injections to those with four different dosages of placebo injections. A placebo is a look-alike substance that contains no active drug. They will see if a single injection of AZA at a standard concentration currently approved by the FDA to treat myelodysplastic syndromes, can also safely improve muscle growth and function in children with CP. conditions: Cerebral Palsy conditions: Contracture studyType: INTERVENTIONAL phases: PHASE1 allocation: NON_RANDOMIZED interventionModel: SEQUENTIAL interventionModelDescription: For this Phase 1 trial, we will conduct a dose-escalation study in children having CP who receive 5-Azacytidine (AZA) via a single subcutaneous (SQ) injection two weeks before their surgery, already scheduled to release their contractures. We will use a "3 + 3" dose-escalation design where decisions are based on the rate of toxicity at the current dose level independently from prior dose levels. The primary goal of this study is to determine a Maximum Tolerated Dose (MTD), which will be the highest dose level at which less or equal of 33% of patients experience Dose-Limiting Toxicity (DLT). primaryPurpose: TREATMENT masking: TRIPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: OUTCOMES_ASSESSOR count: 27 type: ESTIMATED name: Placebo for the AZA 10mg/m^2 name: Placebo for the AZA 20mg/m^2 name: Placebo for the AZA 35mg/m^2 name: Placebo for the AZA 75mg/m^2 name: 5-Azacytidine 10mg/m^2 name: 5-Azacytidine 20mg/m^2 name: 5-Azacytidine 35mg/m^2 name: 5-Azacytidine 75mg/m^2 measure: Dose-limiting toxicity (DLT). measure: Satellite Cell Fusion Index. measure: DNA methylation quantification in Satellite Cells and Blood Mononucleated Cells. measure: DNA methylation profiling in Satellite Cells. measure: Chromatin immunoprecipitation sequencing (ChIP-seq), and assay for transposase-accessible chromatin sequencing (ATAC-seq) sex: ALL minimumAge: 2 Years maximumAge: 18 Years stdAges: CHILD stdAges: ADULT hasResults: False